Showing 231-240 of 325 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Determination of autoreactive B lymphocyte development by ROS in T1D | Vanderbilt University Medical Center (VUMC) | Christopher Wilson | Cures | 01-July-2023 to 30-June-2026 | $234.766,00 |
| Tolerance signals from human pregnancy for beta cell replacement therapy | University of Florida | Edward Phelps | Cures | 01-December-2023 to 30-November-2025 | $600.000,00 |
| Development and Preclinical Assessment of a Biovascular Pancreas | Humacyte | Kaleb Naegeli | Cures | 01-April-2023 to 28-February-2027 | $863.333,00 |
| Transcriptional modulation by BET bromodomain inhibitors in beta cells | The Medical College of Wisconsin Inc. | Joshua Nord | Cures | 01-March-2023 to 28-February-2026 | $221.638,00 |
| Novel insulin formulations for pumps | Stanford University | Yanxian Zhang | Improving Lives | 01-March-2023 to 28-February-2026 | $243.986,00 |
| Pancreatic Lymph Node T cell Composition and Function in Human Type 1 Diabetes | Trustees of the University of Pennsylvania | Gregory Golden | Cures | 01-April-2023 to 31-March-2026 | $214.356,00 |
| Defining and applying neo-epitope specific TCRs for engineered cell therapy | Benaroya Research Institute at Virginia Mason | Aïsha Callebaut | Cures | 01-March-2023 to 28-February-2026 | $205.273,00 |
| Genome-scale CRISPR screens identify ER export cargo proteins as mediators for β-cell stress response and antigen presentation | Indiana Biosciences Research Institute | Isabela Lovizutto Iessi Longo | Cures | 01-March-2023 to 28-February-2026 | $135.307,11 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212.708,89 |
| ROLE OF ZBED3 IN BETA CELL STRESS RESPONSE AND VULNERABILITY AGAINST AUTOIMMUNITY | Indiana Biosciences Research Institute | Erica Cai | Cures | 01-March-2023 to 29-February-2028 | $999.737,71 |